Literature DB >> 19707240

Hematology: Azacitidine improves survival in myelodysplastic syndromes.

Michal G Rose1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19707240     DOI： 10.1038/nrclinonc.2009.125

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.

Authors:  Michael Lübbert; Stefan Suciu; Liliana Baila; Björn Hans Rüter; Uwe Platzbecker; Aristoteles Giagounidis; Dominik Selleslag; Boris Labar; Ulrich Germing; Helmut R Salih; Filip Beeldens; Petra Muus; Karl-Heinz Pflüger; Corneel Coens; Anne Hagemeijer; Hans Eckart Schaefer; Arnold Ganser; Carlo Aul; Theo de Witte; Pierre W Wijermans
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

2.  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Authors:  Alan List; Gordon Dewald; John Bennett; Aristotle Giagounidis; Azra Raza; Eric Feldman; Bayard Powell; Peter Greenberg; Deborah Thomas; Richard Stone; Craig Reeder; Kenton Wride; John Patin; Michele Schmidt; Jerome Zeldis; Robert Knight
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

3.  International scoring system for evaluating prognosis in myelodysplastic syndromes.

Authors:  P Greenberg; C Cox; M M LeBeau; P Fenaux; P Morel; G Sanz; M Sanz; T Vallespi; T Hamblin; D Oscier; K Ohyashiki; K Toyama; C Aul; G Mufti; J Bennett
Journal:  Blood       Date:  1997-03-15       Impact factor: 22.113

4.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Authors:  Lewis R Silverman; Erin P Demakos; Bercedis L Peterson; Alice B Kornblith; Jimmie C Holland; Rosalie Odchimar-Reissig; Richard M Stone; Douglas Nelson; Bayard L Powell; Carlos M DeCastro; John Ellerton; Richard A Larson; Charles A Schiffer; James F Holland
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

5.  Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study.

Authors:  Alice B Kornblith; James E Herndon; Lewis R Silverman; Erin P Demakos; Rosalie Odchimar-Reissig; James F Holland; Bayard L Powell; Carlos DeCastro; John Ellerton; Richard A Larson; Charles A Schiffer; Jimmie C Holland
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

6.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman
Journal:  Lancet Oncol       Date:  2009-02-21       Impact factor: 41.316

7.  Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

Authors:  Azra Raza; James A Reeves; Eric J Feldman; Gordon W Dewald; John M Bennett; H Joachim Deeg; Luke Dreisbach; Charles A Schiffer; Richard M Stone; Peter L Greenberg; Peter T Curtin; Virginia M Klimek; Jamile M Shammo; Deborah Thomas; Robert D Knight; Michele Schmidt; Kenton Wride; Jerome B Zeldis; Alan F List
Journal:  Blood       Date:  2007-09-24       Impact factor: 22.113

8.  Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes.

Authors:  Luca Malcovati; Ulrich Germing; Andrea Kuendgen; Matteo G Della Porta; Cristiana Pascutto; Rosangela Invernizzi; Aristoteles Giagounidis; Barbara Hildebrandt; Paolo Bernasconi; Sabine Knipp; Corinna Strupp; Mario Lazzarino; Carlo Aul; Mario Cazzola
Journal:  J Clin Oncol       Date:  2007-08-10       Impact factor: 44.544

9.  Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine.

Authors:  Gautam Borthakur; Samih El Ahdab; Farhad Ravandi; Stefan Faderl; Alessandra Ferrajoli; Beth Newman; Jean-Pierre Issa; Hagop Kantarjian
Journal:  Leuk Lymphoma       Date:  2008-04

10.  Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.

Authors:  Roger M Lyons; Thomas M Cosgriff; Sanjiv S Modi; Robert H Gersh; John D Hainsworth; Allen L Cohn; Heidi J McIntyre; Indra J Fernando; Jay T Backstrom; C L Beach
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544
  10 in total
  2 in total

Review 1.  Epimutation and cancer: a new carcinogenic mechanism of Lynch syndrome (Review).

Authors:  Kouji Banno; Iori Kisu; Megumi Yanokura; Kosuke Tsuji; Kenta Masuda; Arisa Ueki; Yusuke Kobayashi; Wataru Yamagami; Hiroyuki Nomura; Eiichiro Tominaga; Nobuyuki Susumu; Daisuke Aoki
Journal:  Int J Oncol       Date:  2012-06-25       Impact factor: 5.650

2.  Gene-Set Local Hierarchical Clustering (GSLHC)--A Gene Set-Based Approach for Characterizing Bioactive Compounds in Terms of Biological Functional Groups.

Authors:  Feng-Hsiang Chung; Zhen-Hua Jin; Tzu-Ting Hsu; Chueh-Lin Hsu; Hsueh-Chuan Liu; Hoong-Chien Lee
Journal:  PLoS One       Date:  2015-10-16       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.